RxDoctor Payments Data

Tamika Cummings

Nurse Practitioner · Boca Raton, FLNPI 1457861080

Payments from drug & device makers

$4,395in general payments, 2019–2025

Across 238 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$759
  • Lilly USA, LLC$585
  • AbbVie$383
  • AstraZeneca$343
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$280
  • Bayer$257
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$4,395100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,395 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$12,566
Medicare patients
114
Services billed
150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin25$25,760
EliquisApixaban15$19,891
MounjaroTirzepatide14$16,631
MyrbetriqMirabegron11$14,718
EntrestoSacubitril/Valsartan12$9,225
Albuterol Sulfate HfaAlbuterol Sulfate45$1,171
Atorvastatin Calcium123$1,058
Gabapentin54$998
Ropinirole Hcl14$705
Ventolin HfaAlbuterol Sulfate11$635
Amlodipine Besylate130$603
Losartan Potassium64$600
Pantoprazole Sodium62$489
Metoprolol Succinate21$473
Levothyroxine Sodium38$316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$243$25,76025 claims
PfizerEliquis$256$19,89115 claims
Lilly USA, LLCMounjaro$585$16,63114 claims
Astellas Pharma US IncMyrbetriq$30$14,71811 claims
NovartisEntresto$149$9,22512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →